Review article: Interferon and hepatitis C factors predicting therapeutic outcome

C. L. Mabee, J. S. Crippin, W. M. Lee

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Hepatitis C chronically infects ≃ 1.5% of Americans and is the most common clinical problem facing hepatologists. Since the virus was initially described in 1989, development of an effective therapy has been challenging. Although several different therapeutic agents have been used, no therapy has been shown to reliably eradicate the virus. Interferon-alpha, a cytokine with immunostimulatory and anti-viral properties, has become the therapy of choice for patients with chronic hepatitis C infection. Trials assessing the efficacy of interferon-alpha have characterized host and viral factors predictive of responses to treatment. A thorough understanding of these predictive factors is requisite to providing cost-effective therapeutic decisions for the patient with chronic hepatitis C infection.

Original languageEnglish (US)
Pages (from-to)509-518
Number of pages10
JournalAlimentary Pharmacology and Therapeutics
Volume12
Issue number6
DOIs
StatePublished - 1998

Fingerprint

Hepatitis C
Interferons
Chronic Hepatitis C
Interferon-alpha
Therapeutics
Viruses
Infection
Cytokines
Costs and Cost Analysis

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Review article : Interferon and hepatitis C factors predicting therapeutic outcome. / Mabee, C. L.; Crippin, J. S.; Lee, W. M.

In: Alimentary Pharmacology and Therapeutics, Vol. 12, No. 6, 1998, p. 509-518.

Research output: Contribution to journalArticle

@article{f004fbaf895e4dbf89943389d451924e,
title = "Review article: Interferon and hepatitis C factors predicting therapeutic outcome",
abstract = "Hepatitis C chronically infects ≃ 1.5{\%} of Americans and is the most common clinical problem facing hepatologists. Since the virus was initially described in 1989, development of an effective therapy has been challenging. Although several different therapeutic agents have been used, no therapy has been shown to reliably eradicate the virus. Interferon-alpha, a cytokine with immunostimulatory and anti-viral properties, has become the therapy of choice for patients with chronic hepatitis C infection. Trials assessing the efficacy of interferon-alpha have characterized host and viral factors predictive of responses to treatment. A thorough understanding of these predictive factors is requisite to providing cost-effective therapeutic decisions for the patient with chronic hepatitis C infection.",
author = "Mabee, {C. L.} and Crippin, {J. S.} and Lee, {W. M.}",
year = "1998",
doi = "10.1046/j.1365-2036.1998.00328.x",
language = "English (US)",
volume = "12",
pages = "509--518",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Review article

T2 - Interferon and hepatitis C factors predicting therapeutic outcome

AU - Mabee, C. L.

AU - Crippin, J. S.

AU - Lee, W. M.

PY - 1998

Y1 - 1998

N2 - Hepatitis C chronically infects ≃ 1.5% of Americans and is the most common clinical problem facing hepatologists. Since the virus was initially described in 1989, development of an effective therapy has been challenging. Although several different therapeutic agents have been used, no therapy has been shown to reliably eradicate the virus. Interferon-alpha, a cytokine with immunostimulatory and anti-viral properties, has become the therapy of choice for patients with chronic hepatitis C infection. Trials assessing the efficacy of interferon-alpha have characterized host and viral factors predictive of responses to treatment. A thorough understanding of these predictive factors is requisite to providing cost-effective therapeutic decisions for the patient with chronic hepatitis C infection.

AB - Hepatitis C chronically infects ≃ 1.5% of Americans and is the most common clinical problem facing hepatologists. Since the virus was initially described in 1989, development of an effective therapy has been challenging. Although several different therapeutic agents have been used, no therapy has been shown to reliably eradicate the virus. Interferon-alpha, a cytokine with immunostimulatory and anti-viral properties, has become the therapy of choice for patients with chronic hepatitis C infection. Trials assessing the efficacy of interferon-alpha have characterized host and viral factors predictive of responses to treatment. A thorough understanding of these predictive factors is requisite to providing cost-effective therapeutic decisions for the patient with chronic hepatitis C infection.

UR - http://www.scopus.com/inward/record.url?scp=0031863782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031863782&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.1998.00328.x

DO - 10.1046/j.1365-2036.1998.00328.x

M3 - Article

C2 - 9678809

AN - SCOPUS:0031863782

VL - 12

SP - 509

EP - 518

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 6

ER -